Get started
Author

Ioanna Vlachaki

Observed names: I Vlachaki, I. Vlachaki, Vlachaki, Ioanna
Institution: Chiesi (Italy)
ORCID: 0000-0002-9306-3750
Observed ORCID: 0000-0002-9306-3750
OpenAlex ID: A5015623723
Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy
2019 · Jason Foo, Mohamad Maghnie, et al. · ClinicoEconomics and Outcomes Research · 16
PDF
188O EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy
2023 · J. Cortés, F.C. Bidard, et al. · ESMO Open · 10
PDF
Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis
2021 · Ioanna Vlachaki, Matteo Vacchelli, et al. · BMC Infectious Diseases · 10
PDF
Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective
2022 · Daniela Zinzi, Ioanna Vlachaki, et al. · The European Journal of Health Economics · 8
PDF
Single inhaler with beclometasone, formoterol, and glycopyrronium versus triple therapies in adults with uncontrolled asthma: a systematic review and meta-analysis
2025 · Fulvio Braido, Ioanna Vlachaki, et al. · Scientific Reports · 7
PDF
Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy
2021 · Francesco Saverio Mennini, Mario Gori, et al. · Health Economics Review · 6
PDF
Cost-effectiveness analysis of vaborem for the treatment of carbapenem-resistant Enterobacteriaceae-Klebsiella pneumoniae carbapenemase (CRE-KPC) infections in the UK
2021 · Ioanna Vlachaki, Daniela Zinzi, et al. · The European Journal of Health Economics · 6
PDF
A Systematic Literature Review of the Humanistic, Economic, Sociodemographic, and Environmental Burden Associated with Severe COPD
2025 · Ioanna Vlachaki, Simon Donhauser, et al. · International Journal of COPD · 5
A systematic review of the humanistic, economic, sociodemographic, and environmental burden of severe/difficult-to-treat asthma
2025 · Arnaud Bourdin, Ioanna Vlachaki, et al. · Current Medical Research and Opinion · 3
PDF
Patent Expiry and Generic Pricing: The Impact on Cost- Effectiveness Results
2015 · A Hirst, D Murphy, et al. · Value in Health · 2
A cost-effectiveness analysis comparing single-inhaler extrafine beclomethasone/formoterol/glycopyrronium bromide against other SITTs in adult patients with uncontrolled asthma in England
2025 · Ioanna Vlachaki, Simon Donhauser, et al. · Health Economics Review · 1
PDF
Cost Minimisation Analysis: When And Where? A Review Of Hta Guidance On Cost Minimisation Analysis
2016 · A Hirst, I Vlachaki, et al. · Value in Health · 1
Economic and Environmental Value of Low-GWP propellant pMDIs – A Multi-Country Impact Analysis
2026 · Sukanya Venkada Subramaniyan, Job F. M. van Boven, et al. · ERJ Open Research
What is the Current Clinical and Economic Burden of Difficult to Treat or Severe Asthma and Severe COPD in the US?
2025 · I. Vlachaki, S. Donhauser, et al. · American Journal of Respiratory and Critical Care Medicine
PCR219 Humanistic and Economic Burden of Severe Chronic Obstructive Pulmonary Disease (COPD)
2024 · I. Vlachaki, S. Donhauser, et al. · Value in Health
PDF
P178 A global systematic literature review to investigate the impact of environmental factors on the prevalence, control and severity of severe or difficult-to-treat asthma
2024 · I Vlachaki, S Donhauser, et al. · Thorax
M24 A global systematic literature review to investigate the humanistic and economic burden of severe chronic obstructive pulmonary disease (COPD)
2024 · I Vlachaki, S Donhauser, et al. · Thorax
PIN25 Cost-Effectiveness of Vaborem for the Treatment of CRE-KPC Infections in Italy
2020 · F. Fiorentino, P. La Malfa, et al. · Value in Health
PDF
Pdb60 - Cost-consequence Analysis for Recombinant Human Growth Hormone Treatment Administered Via Different Devices in Children With Growth Hormone Deficiency in Italy
2018 · C. Centonze, J. Foo, et al. · Value in Health
PDF
Comparison of Recent Hta Appraisals of Orphan Drugs By Nice, SMC And Has In 2015-2017
2017 · J Ziomek, I Vlachaki, et al. · Value in Health
PDF
Have Budget Impact Analyses Included Clinical Outcomes?
2016 · J Wang-Silvanto, M Taylor, et al. · Value in Health
Requirements for Economic Evidence Across Different HTA Bodies
2016 · I Vlachaki, J Wang-Silvanto, et al. · Value in Health
Nice Decision Making: To Appeal or not to Appeal?
2015 · I Vlachaki, D Murphy, et al. · Value in Health
PDF
Surgery As An Outcome In Cost-Effectiveness Analysis
2015 · D Murphy, I Vlachaki, et al. · Value in Health
Trends in Non-Submissions in the UK
2015 · D Murphy, I Vlachaki, et al. · Value in Health
Works count: 26
Citation count: 75
H-index: 6
I10-index: 3
Year
Topic
Type